Role of Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients with Aml or High Risk Mds

Background: Hematologic malignancies are more common among older patients. This age group has historically had worse outcomes when compared with younger counterparts. Allogeneic hematopoietic stem cell transplantation (HSCT) can achieve durable remissions in a number of patients with advanced hematologic malignancies, but its application to the elderly has been traditionally limited by arbitarry age restrictions, reflecting concerns of high rates of nonrelapse mortality and morbidity. Although the advent of reduced intensity conditioning regimens has extended HSCT to increasingly older adoults, little is knowm about the role of HSCT in practice.